SynAct Pharma (SYNACT.ST) Stock Analysis & AI Equity Report
SynAct Pharma (SYNACT.ST) overview
SynAct Pharma (SYNACT.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, SynAct Pharma reported revenue of SEK 0m and operating profit of SEK -117m; the year-end share price was 22.60 SEK and market capitalisation was SEK 1,154m. SynAct Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get SynAct Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About SynAct Pharma
SynAct Pharma AB is a clinical-stage biotechnology company developing treatments that aim to resolve inflammation rather than suppress the immune system. Its lead candidate, resomelagon (AP1189), is an oral melanocortin agonist in clinical development, alongside injectable peptide compounds. The company focuses on inflammatory and autoimmune diseases, including rheumatoid arthritis, and host-directed treatment in viral infections.
Generate the SynAct Pharma report
SynAct Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for SynAct Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.